文献速递膀胱癌与上尿路尿路上皮癌

接受肾输尿管切除术治疗且诊断为组织学变异的上尿路尿路上皮癌患者的发病率和生存结局

Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy.
PubMed 文献 · BJU Int · 2019-04-07

该多中心回顾性研究分析了1990至2016年间1610例接受根治性肾输尿管切除术(RNU)的临床非转移性上尿路尿路上皮癌(UTUC)患者,其中150例(9%)存在组织学变异。与纯尿路上皮癌相比,变异组织学与不良病理特征相关;竞争风险分析显示,微乳头变异是唯一与更差复发相关的因素,肉瘤样变异与更差癌症特异性死亡相关。

要点

  • 接受RNU的UTUC患者中约十分之一存在组织学变异。
  • 变异组织学与更晚期病理特征相关。
  • 微乳头变异与更差复发相关,肉瘤样变异与更差癌症特异性死亡相关。

核心结论

  • 在接受RNU治疗的UTUC患者中,每10例就有1例存在组织学变异。
  • 在校正可用混杂因素后,仅微乳头和肉瘤样变异与更差的肿瘤学结局相关。

研究设计与样本

  • 多中心回顾性分析,纳入1990年至2016年间接受RNU治疗的临床非转移性UTUC患者1610例。

主要发现

  • 1460例(91%)为纯尿路上皮癌(PUC),150例(9%)诊断为组织学变异,其中微乳头89例(5.0%)、鳞状41例(2.0%)、肉瘤样10例(1.0%)和其他10例(1.0%)。
  • 与PUC相比,变异组织学与不良病理特征相关:非器官局限性疾病59% vs 38%(P < 0.001)、淋巴结侵犯28% vs 24%(P = 0.02)、高级别疾病88% vs 71%(P < 0.001)、肿瘤坏死28% vs 16%(P = 0.001)和手术切缘阳性15% vs 8%(P = 0.01)。
  • 竞争风险分析中,微乳头变异是唯一与更差复发相关的因素(sub-hazard ratio [SHR] 2.27,95% confidence interval [CI] 1.25-4.79;P = 0.02)。
  • 肉瘤样变异与更差癌症特异性死亡相关(SHR 16.8,95% CI 6.86-41.17;P < 0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the incidence and survival outcomes of histological variants of upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). MATERIALS AND METHODS: We retrospectively analysed data from 1610 patients treated with RNU for clinically non-metastatic UTUC between 1990 and 2016 in several centres participating in the UTUC Collaboration. Histological variants were classified as micropapillary, squamous, sarcomatoid and other, including other rare variants (<10 cases for each). Multivariable competing risk analyses were conducted to assess the effect of variant histology on overall recurrence and cancer-specific mortality (CSM). RESULTS: Overall, 1460 patients (91%) had pure urothelial carcinoma (PUC), whereas 150 (9%) were diagnosed with a variant histology, including 89 (5.0%), 41 (2.0%), 10 (1.0%) and 10 (1.0%) cases of micropapillary, squamous, sarcomatoid and other tumours, respectively. Variant histology was associated with the presence of adverse pathological features compared with PUC, including non-organ-confined disease (59% vs 38%; P < 0.001), lymph node invasion (28% vs 24%; P = 0.02), high-grade disease (88% vs 71%; P < 0.001), tumour necrosis (28% vs 16%; P = 0.001) and positive surgical margins (15% vs 8%; P = 0.01). In competing risk analysis, micropapillary variant was the only factor associated with worse recurrence (sub-hazard ratio [SHR] 2.27, 95% confidence interval [CI] 1.25-4.79; P = 0.02) whereas sarcomatoid variant was associated with worse CSM (SHR 16.8, 95% CI 6.86-41.17; P < 0.001). CONCLUSION: We found that one out of 10 patients with UTUC treated with RNU had variant histology. Only micropapillary and sarcomatoid variants were associated with poorer oncological outcomes after adjusting for available confounding factors.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Zamboni S, Foerster B, Abufaraj M, et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU Int. 2019. PMID: 30908835. doi:10.1111/bju.14751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。